AccessibilityHelp
Addex Therapeutics logo

Addex Therapeutics(NASDAQ) ADXN

Market Cap$3.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-98%
1 Year-67%
1 Month-17%
$2.97
+2.69%
+0.08Today
Addex Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.892026-10-22
Addex Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.24%USD 3.022026-10-15
1 month-17.37%USD 3.502026-09-22
3 month-50.86%USD 5.892026-07-24
Year to date-62.54%USD 7.722025-12-31
1 year-66.76%USD 8.702025-10-22
3 year-55.09%USD 6.442023-10-23
5 year-98.16%USD 157.602021-10-22
Since inception-99%USD 290.002020-01-29

Addex Therapeutics Financials at a Glance

Market Cap

$3.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 47.57K

Net Income (TTM)

-CHF 6.86M

EPS (TTM)

-$8.81

P/E Ratio

-0.33

Dividend

$0.00

Beta (Volatility)

0.45 (Low)

Price

$2.97

Volume

4,566.056

Open

$3.00

Previous Close

$2.89

Daily Range

$2.97 - $3.00

52-Week Range

$2.56 - $10.43

Estimated Earnings Date

Nov 9, 2026

ADXN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Addex Therapeutics

Addex Therapeutics Ltd is a biopharmaceutical company based in Switzerland, focused on developing small-molecule drugs for central nervous system (CNS) disorders. The company specializes in discovering and advancing allosteric modulators for G-protein coupled receptors, with key programs targeting conditions such as Parkinson's disease and epilepsy.

Products and Services
  • Dipraglurant: Investigational treatment for Parkinson's disease levodopa-induced dyskinesia
  • ADX71149: Developed for epilepsy and other CNS conditions
  • GABAB PAM: A compound aimed at treating addiction
Growth Outlook
  • Strong pipeline with multiple CNS-targeted therapies in development
  • Collaborations with major partners like Janssen Pharmaceuticals and Indivior PLC
  • Potential market expansion as CNS disorders gain increased attention
Financial Highlights
  • Recent quarterly revenue of 9,908 CHF, showing growth potential
  • Trailing twelve months (TTM) revenue of 38,815 CHF, indicating ongoing development
  • Cash and short-term investments totaled 767,328 CHF as of June 30, 2026
Addex Therapeutics Ltd operates in a promising sector with a focus on innovative treatments for CNS disorders. The company's strategic partnerships and robust pipeline position it well for future growth. Recent financial data reflects ongoing investment in research and development, essential for advancing its therapeutic candidates. The company continues to navigate the complexities of the biopharmaceutical landscape while aiming to address significant unmet medical needs.
AI Generated • Oct 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

3

CEO

Tim Dyer

Website

www.addextherapeutics.com

Headquarters

Geneva, GE 1202, CH

ADXN Financials

Key Financial Metrics (TTM)

Gross Margin

41.19%

Operating Margin

-4115.07%

Net Income Margin

-10874.58%

Return on Equity

-172.76%

Return on Capital

-58.62%

Return on Assets

-197.62%

Earnings Yield

-3.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.06M

Volume

4.57K

Avg. Volume

137.14K

Financials (TTM)

Gross Profit

-CHF 13.68K

Operating Income

-CHF 2.60M

EBITDA

-CHF 5.72M

Operating Cash Flow

-CHF 2.38M

Capital Expenditure

-CHF 3.94

Free Cash Flow

-CHF 2.38M

Cash & ST Invst.

CHF 767.33K

Total Debt

CHF 77.50K

Addex Therapeutics Performance Analysis

Addex Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 1,512,943-52.9%
20232023-12-31CHF 1,799,57118.9%
20242024-12-31CHF 465,604-74.1%
20252025-12-31CHF 208,143-55.3%
Addex Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-18.3%
Q42025-12-31-99.2%
Q12026-03-313001.2%
Q22026-06-3028.8%
Addex Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -57.85-2.0%
20232023-12-31CHF -18.97-67.2%
20242024-12-31CHF 5.73N/A
20252025-12-31CHF -9.05N/A
Addex Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3030.5%
Q42025-12-317.9%
Q12026-03-3121.9%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CHF 9.91K

-72.8%

Gross Profit

-CHF 15.22K

+92.3%

Gross Margin

-1.54%

N/A

Market Cap

$3.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.02M

N/A

Employees

3

N/A

Net Income

-CHF 1.74M

+5.6%

EBITDA

-CHF 617.70K

+68.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CHF 767.33K

-66.7%

Total Debt

CHF 77.50K

+101.9%

Accounts Receivable

CHF 29.75K

-22.6%

Inventory

CHF 0.00

N/A

Long Term Debt

CHF 23.02K

-25.5%

Short Term Debt

CHF 54.47K

+627.2%

Return on Assets

-1.98%

N/A

Return on Invested Capital

-1.23%

N/A

Free Cash Flow

-CHF 468.70K

-11.6%

Operating Cash Flow

-CHF 468.69K

-11.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRSNNeuroSense Therapeutics Ltd.
$2.42-0.82%
RADXRadiopharm Theranostics Limited
$1.00+5.26%
CDIOCardio Diagnostics Holdings, Inc.
$1.75+2.64%
TCRTAlaunos Therapeutics, Inc.
$2.29-24.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.86+2.15%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$84.32+2.69%
NOKNokia
$8.10+2.79%
RWMProShares Trust - ProShares Short Russell2000
$14.57+0.45%

Questions About ADXN

What is the current price of Addex Therapeutics?

Addex Therapeutics is trading at $2.97 per share.

What is the 52-week range for Addex Therapeutics?

Over the past 52 weeks, Addex Therapeutics has traded between $2.56 and $10.43.

How much debt does Addex Therapeutics have?

As of the most recent reporting period, Addex Therapeutics reported total debt of CHF 96.07K.

How much cash does Addex Therapeutics have on hand?

Addex Therapeutics reported CHF 951.25K in cash and cash equivalents in its most recent financial results.

What is Addex Therapeutics’s dividend yield?

Addex Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services